SymBio Pharmaceuticals
SymBio Pharmaceuticals aims to develop drugs for patients overlooked by the industry, ensuring vital treatments reach those in need.
Launch date
Employees
Market cap
CAD116m
Enterprise valuation
CAD49m (Public information from Sep 2024)
Share price
JPY252 4582.T
Durham North Carolina (HQ)
Financials
Estimates*
| JPY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 2.8b | 3.0b | 8.3b | 10.0b | 5.6b | 1.7b |
| % growth | - | 5 % | 176 % | 21 % | (44 %) | (70 %) |
| EBITDA | (4.3b) | (5.0b) | 1.1b | 2.0b | (249m) | - |
| % EBITDA margin | (150 %) | (166 %) | 13 % | 20 % | (4 %) | - |
| Profit | (4.4b) | (4.1b) | 2.0b | 1.2b | (2.0b) | - |
| % profit margin | (154 %) | (137 %) | 25 % | 12 % | (35 %) | - |
| EV / revenue | - | - | - | 1.9x | 0.7x | - |
| EV / EBITDA | - | - | - | 9.8x | -15.7x | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Seed | ||
N/A | Series A | ||
| N/A | JPY4.9m | Early VC | |
JPY2.0b | Series B | ||
JPY718m | Late VC | ||
$618m | Late VC | ||
$24.0m | Series E | ||
| N/A | N/A | IPO | |
JPY1.0b | Post IPO Equity | ||
JPY3.0b | Post IPO Debt | ||
| Total Funding | CAD904m | ||
Related Content
Recent News about SymBio Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.